Literature DB >> 16978076

Can the clinical pulmonary infection score impact ICU antibiotic days?

Sandra M Swoboda1, Tara Dixon, Pamela A Lipsett.   

Abstract

BACKGROUND: The Clinical Pulmonary Infection Score (CPIS) has been used in the intensive care unit (ICU) as a decision tool for initiation of antibiotics in suspected pneumonia and also for discontinuing antibiotics if the CPIS score is <or=6 on day three of therapy, but it is not in common clinical use. We sought to determine if application of a CPIS score<or=6 at three days could reduce antibiotic use and if a blinded committee would have a greater percentage of patients with CPIS>6 on day one receiving antibiotics empirically for pneumonia.
METHODS: Over 11 months, we evaluated empiric antibiotics prospectively in two ICUs of a large tertiary university teaching hospital. A pneumonia committee (PC) reviewed all patients and defined pneumonia according to the guidelines of the U.S. Centers for Disease Control and Prevention (CDC). The CPIS was calculated for all patients at day one and day three of antibiotic therapy. The percentage of patients with a CPIS<or=6 was compared for the ICU and PC, and the total antibiotic days potentially saved by using CPIS<or=6 as the criterion for treatment were determined. Receiver operating characteristic (ROC) curves and inter-observer reliability were determined.
RESULTS: Three hundred twelve patients received empiric antibiotics, 83 of whom were believed to have pneumonia by the ICU staff (2,283 antibiotic days). On day one, the 55 patients started on antibiotics had a CPIS<or=6, with 1,460 antibiotic-days, and only 28 patients had a CPIS>6 (823 antibiotic-days). In contrast, the PC determined 19 patients (23%) to have pneumonia by the CDC definition (731 antibiotic-days), with eight of these patients having a CPIS<or=6 and 11 a CPIS>6. Pneumonia committee review resulted in fewer patients believed to have pneumonia and a greater percentage with a CPIS>6 (odds ratio [OR] 2.7; 95% confidence interval [CI] 0.86, 8.6; p=0.05). Restriction of antibiotics to patients with a CPIS>6 would have saved 1,460 antibiotic-days at day one and 1,053 days if treatment was delayed until day three. Clinical Pulmonary Infection Score ROC curves for the PC showed an area under the curve (AUC) of 0.82 (95% CI 0.72, 0.91), whereas the AUC for the ICU group was 0.85 (95% CI 0.79, 0.92). The sensitivity and specificity of a CPIS>6 for the PC were 79% and 75%, respectively, with correct prediction 76% of the time. The inter-observer reliability of the CPIS had a kappa value of 0.88.
CONCLUSIONS: This prospective evaluation confirms that 50% of antibiotic-days in our ICU are used empirically for pneumonia when that infection is not likely to be present by either CDC or CPIS criteria. Although the CPIS has good reliability and acceptable sensitivity and specificity, PC review and CPIS<or=6 were commonly divergent (42-47%). Thus, better strategies should be developed for identification of pneumonia and empiric antibiotic administration in the ICU.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978076     DOI: 10.1089/sur.2006.7.331

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  7 in total

1.  COSARA: integrated service platform for infection surveillance and antibiotic management in the ICU.

Authors:  Kristof Steurbaut; Kirsten Colpaert; Bram Gadeyne; Pieter Depuydt; Peter Vosters; Christian Danneels; Dominique Benoit; Johan Decruyenaere; Filip De Turck
Journal:  J Med Syst       Date:  2012-04-18       Impact factor: 4.460

2.  Intubated Trauma Patients Receiving Prolonged Antibiotics for Pneumonia despite Negative Cultures: Predictors and Outcomes.

Authors:  Tyler J Loftus; Scott C Brakenridge; Frederick A Moore; Stephen J Lemon; Linda L Nguyen; Stacy A Voils; Janeen R Jordan; Chasen A Croft; R Stephen Smith; Phillip A Efron; Alicia M Mohr
Journal:  Surg Infect (Larchmt)       Date:  2016-09-16       Impact factor: 2.150

3.  Variability in Diagnosis and Treatment of Ventilator-Associated Pneumonia in Neurocritical Care Patients.

Authors:  Atul A Kalanuria; Donna Fellerman; Paul Nyquist; Romergryko Geocadin; Robert G Kowalski; Veronique Nussenblatt; Matthew Rajarathinam; Wendy Ziai
Journal:  Neurocrit Care       Date:  2015-08       Impact factor: 3.210

4.  Identifying missed opportunities to curtail antimicrobial therapy for presumed ventilator-associated pneumonia using the clinical pulmonary infection score.

Authors:  Sean K Gorman; Lynne-Michelle M Stewart; Richard S Slavik; Jane de Lemos; Dean Chittock; Vinay K Dhingra; Juan J Ronco; Harjinder Parwana
Journal:  Can J Hosp Pharm       Date:  2009-05

5.  Early bronchoalveolar lavage for intubated trauma patients with TBI or chest trauma.

Authors:  Tyler J Loftus; Stephen J Lemon; Linda L Nguyen; Stacy A Voils; Scott C Brakenridge; Janeen R Jordan; Chasen A Croft; R Stephen Smith; Frederick A Moore; Philip A Efron; Alicia M Mohr
Journal:  J Crit Care       Date:  2017-02-12       Impact factor: 3.425

Review 6.  Ventilator-associated pneumonia in the ICU.

Authors:  Atul Ashok Kalanuria; Wendy Ziai; Wendy Zai; Marek Mirski
Journal:  Crit Care       Date:  2014-03-18       Impact factor: 9.097

7.  Rethinking the "Pan-Culture": Clinical Impact of Respiratory Culturing in Patients With Low Pretest Probability of Ventilator-Associated Pneumonia.

Authors:  Owen R Albin; Louis Saravolatz; Joshua Petrie; Oryan Henig; Keith S Kaye
Journal:  Open Forum Infect Dis       Date:  2022-04-14       Impact factor: 4.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.